124 related articles for article (PubMed ID: 26032009)
1. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol.
Afsar B; Agca E; Turk S
J Clin Pharmacol; 2015 Nov; 55(11):1280-5. PubMed ID: 26032009
[TBL] [Abstract][Full Text] [Related]
2. The Predictive Value of Platelet/Lymphocyte Ratio in Hemodialysis Patients With Erythropoietin Resistance.
Taymez DG; Ucar E; Turkmen K; Ucar R; Afsar B; Gaipov A; Turk S
Ther Apher Dial; 2016 Apr; 20(2):118-21. PubMed ID: 26929254
[TBL] [Abstract][Full Text] [Related]
3. The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients.
Afsar B; Saglam M; Yuceturk C; Agca E
Eur J Intern Med; 2013 Apr; 24(3):e25-9. PubMed ID: 23246125
[TBL] [Abstract][Full Text] [Related]
4. The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores.
Afsar B
Int J Artif Organs; 2013 May; 36(5):314-9. PubMed ID: 23645578
[TBL] [Abstract][Full Text] [Related]
5. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
6. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
[TBL] [Abstract][Full Text] [Related]
7. EFFECTS OF VITAMIN D ANALOGS ON ERYTHROPOIESIS-STIMULATING AGENT DASAGE AND SECONDARY ANEMIA IN HEMODIALYSIS PATIENTS.
Varim C; Sipahi S; Yaylaci S; Kaya T; Nalbant A
Georgian Med News; 2016 Mar; (252):26-32. PubMed ID: 27119831
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
[TBL] [Abstract][Full Text] [Related]
11. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
13. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
[TBL] [Abstract][Full Text] [Related]
14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
15. Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report.
Fusaro M; D'Angelo A; Naso A; Frigo AC; Miozzo D; Gallieni M; Calò LA
Ren Fail; 2011; 33(7):732-5. PubMed ID: 21671845
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
17. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
[TBL] [Abstract][Full Text] [Related]
18. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.
Riccio E; Sabbatini M; Bruzzese D; Capuano I; Migliaccio S; Andreucci M; Pisani A
PLoS One; 2015; 10(3):e0118174. PubMed ID: 25781618
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease.
Sözel H; Köksoy S; Ozdem S; Yılmaz F; Bora F; Ersoy FF
Int Urol Nephrol; 2020 Aug; 52(8):1563-1570. PubMed ID: 32405698
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
